{"title": "Inhibici\u00f3n de PCSK9: una nueva alternativa para reducir el colesterol y prevenir la enfermedad cardiovascular aterosclerosa", "author": "Administrador", "url": "https://medicinainterna.org.mx/article/inhibicion-de-pcsk9-una-nueva-alternativa-para-reducir-el-colesterol-y-prevenir-la-enfermedad-cardiovascular-aterosclerosa/", "hostname": "medicinainterna.org.mx", "description": null, "sitename": "medicinainterna.org.mx", "date": "2019-03-22", "id": null, "license": null, "body": null, "comments": "Sin comentarios", "commentsbody": null, "raw_text": null, "text": "Inhibici\u00f3n de PCSK9: una nueva alternativa para reducir el colesterol y prevenir la enfermedad cardiovascular aterosclerosa\nMed Int M\u00e9x. 2017 marzo;33(2):226-237.\nMonta\u00f1o-Sosa M1, Arag\u00f3n-Torres J1, Gir\u00f3n-Arellano I1, Res\u00e9ndiz-Mel\u00e9ndez E1, Ahumada-Ayala M2\n1 Facultad Mexicana de Medicina, Universidad La Salle, Ciudad de M\u00e9xico.\n2 Maestro Em\u00e9rito de la Facultad Mexicana de Medicina de la Universidad La Salle, Departamento de Medicina Interna y Endocrinolog\u00eda, Hospital \u00c1ngeles Pedregal, Ciudad de M\u00e9xico.\nResumen\nLa enfermedad cardiovascular aterosclerosa ocupa el primer lugar mundial en morbilidad y mortalidad. El principal factor de riesgo de enfermedad es el colesterol unido a lipoprote\u00ednas de baja densidad (C-LDL). El tratamiento farmacol\u00f3gico de elecci\u00f3n para reducir el C-LDL son las estatinas; sin embargo, han sido insuficientes para eliminar el riesgo cardiovascular, especialmente en pacientes con formas primarias de hipercolesterolemia relacionadas con mutaciones gen\u00e9ticas, o intolerantes a estatinas. Es de gran importancia el desarrollo de nuevos f\u00e1rmacos para abatir el riesgo que persiste a pesar de la administraci\u00f3n de estatinas. La proconvertasa subtilisina-kexina 9 (PCSK9) es un regulador primordial de la cantidad de receptores de LDL, ya que su funci\u00f3n es dirigir dichos receptores a su destrucci\u00f3n lisosomal. El advenimiento de anticuerpos monoclonales para bloquear la PCSK9 ha permitido mejorar la cantidad y eficiencia de los receptores de LDL, de esto resulta la disminuci\u00f3n notable del colesterol circulante. Hasta el momento, la eficacia e inocuidad de estos anticuerpos resultan aceptables, y los datos preliminares en cuanto a su efecto en la reducci\u00f3n de la morbilidad y mortalidad cardiovasculares son alentadores.\nPALABRAS CLAVE: PCSK9, colesterol, C-LDL, riesgo cardiovascular, anticuerpos monoclonales, estatinas, evolocumab, alirocumab, inclisir\u00e1n.\nInhibition of PCSK9: a new alternative for cholesterol reduction and prevention of atherosclerotic cardiovascular disease.\nMed Int M\u00e9x. 2017 March;33(2):226-237.\nMonta\u00f1o-Sosa M1, Arag\u00f3n-Torres J1, Gir\u00f3n-Arellano I1, Res\u00e9ndiz-Mel\u00e9ndez E1, Ahumada-Ayala M2\n1 Facultad Mexicana de Medicina, Universidad La Salle, Ciudad de M\u00e9xico.\n2 Maestro Em\u00e9rito de la Facultad Mexicana de Medicina de la Universidad La Salle, Departamento de Medicina Interna y Endocrinolog\u00eda, Hospital \u00c1ngeles Pedregal, Ciudad de M\u00e9xico.\nAbstract\nAtherosclerotic cardiovascular disease represents the leading cause of morbidity and mortality in most countries. The main risk factor for developing this disease is low density lipoprotein cholesterol (LDL-C). The pharmacological treatment of choice for reducing LDL-C is statins; however, in spite of the widespread use of statins, these drugs have been insufficient to eliminate cardiovascular risk. This residual risk is most relevant in patients with primary forms of hypercholesterolemia associated with genetic mutations, or in those who are intolerant to statins. The development of new drugs to reduce residual cardiovascular risk is of vital importance. Proprotein convertase subtilisin-kexin 9 (PCSK9) is an important regulator of the amount of LDL receptors since its function is to direct these receptors to their lysosomal destruction. The development of monoclonal antibodies to block extracellular PCSK9 has allowed us to improve the quantity and efficiency of LDL receptors, resulting in a significant decrease in plasma cholesterol. Efficacy and safety of these antibodies is currently considered acceptable and preliminary data are encouraging but still insufficient to assess the favorable impact of these antibodies in reducing cardiovascular morbidity and mortality.\nKEYWORDS: PCSK9; cholesterol; LDL-C; cardiovascular risk; monoclonal antibodies; statins; evolocumab; alirocumab; inclisiran\nCorrespondencia/correspondence\nDr. Miguel Ahumada Ayala", "language": null, "image": null, "pagetype": null, "links": ["#", "https://medicinainterna.org.mx/5653/", "#", "https://medicinainterna.org.mx/5653/", "https://medicinainterna.org.mx/aviso-de-privacidad/", "https://www.revisionporpares.com/index.php/MIM/user", "/contacto/", "https://medicinainterna.org.mx/busqueda/", "https://medicinainterna.org.mx/tag/ancianos/", "https://medicinainterna.org.mx/tag/artritis-reumatoide/", "https://medicinainterna.org.mx/tag/aterosclerosis/", "https://medicinainterna.org.mx/tag/calidad-de-vida/", "https://medicinainterna.org.mx/tag/choque-septico/", "https://medicinainterna.org.mx/tag/cirrosis-hepatica/", "https://medicinainterna.org.mx/tag/coronavirus/", "https://medicinainterna.org.mx/tag/covid-19/", "https://medicinainterna.org.mx/tag/diabetes/", "https://medicinainterna.org.mx/tag/diabetes-mellitus/", "https://medicinainterna.org.mx/tag/diabetes-mellitus-tipo-2/", "https://medicinainterna.org.mx/tag/diagnostico/", "https://medicinainterna.org.mx/tag/dialisis-peritoneal/", "https://medicinainterna.org.mx/tag/educacion-medica/", "https://medicinainterna.org.mx/tag/embarazo/", "https://medicinainterna.org.mx/tag/enfermedad-renal-cronica/", "https://medicinainterna.org.mx/tag/hemodialisis/", "https://medicinainterna.org.mx/tag/hipertension/", "https://medicinainterna.org.mx/tag/hipertension-arterial/", "https://medicinainterna.org.mx/tag/hiperuricemia/", "https://medicinainterna.org.mx/tag/infarto-agudo-de-miocardio/", "https://medicinainterna.org.mx/tag/insuficiencia-cardiaca/", "https://medicinainterna.org.mx/tag/insuficiencia-renal-aguda/", "https://medicinainterna.org.mx/tag/lesion-renal-aguda/", "https://medicinainterna.org.mx/tag/lupus-eritematoso-sistemico/", "https://medicinainterna.org.mx/tag/medicina-interna/", "https://medicinainterna.org.mx/tag/mexico/", "https://medicinainterna.org.mx/tag/nefropatia-diabetica/", "https://medicinainterna.org.mx/tag/neumonia/", "https://medicinainterna.org.mx/tag/obesidad/", "https://medicinainterna.org.mx/tag/pandemia/", "https://medicinainterna.org.mx/tag/pronostico/", "https://medicinainterna.org.mx/tag/rabdomiolisis/", "https://medicinainterna.org.mx/tag/riesgo-cardiovascular/", "https://medicinainterna.org.mx/tag/sars-cov-2/", "https://medicinainterna.org.mx/tag/sepsis/", "https://medicinainterna.org.mx/tag/sindrome-coronario-agudo/", "https://medicinainterna.org.mx/tag/sindrome-metabolico/", "https://medicinainterna.org.mx/tag/tratamiento/", "https://medicinainterna.org.mx/tag/trombosis/", "https://medicinainterna.org.mx/tag/tuberculosis/", "https://medicinainterna.org.mx/tag/vasculitis/", "https://medicinainterna.org.mx/tag/ventilacion-mecanica/", "https://medicinainterna.org.mx/tag/vih/", "https://medicinainterna.org.mx/tag/acido-urico/", "https://medicinainterna.org.mx/category/popups/alflorex-menarini/", "https://medicinainterna.org.mx/category/popups/alflorez-menarini/", "https://medicinainterna.org.mx/category/articulo-de-opinion/", "https://medicinainterna.org.mx/category/articulo-de-revision/", "https://medicinainterna.org.mx/category/articulos-originales/", "https://medicinainterna.org.mx/category/carta-al-editor/", "https://medicinainterna.org.mx/category/caso-clinico/", "https://medicinainterna.org.mx/category/popups/cicloferon-varicela-liomont/", "https://medicinainterna.org.mx/category/consenso/", "https://medicinainterna.org.mx/category/popups/coriatros-siegfried-rhein/", "https://medicinainterna.org.mx/category/popups/coriatros-siegfried-rhein-sin-ipp/", "https://medicinainterna.org.mx/category/popups/coriatros-siegfried-sin-ipp/", "https://medicinainterna.org.mx/category/popups/cortax/", "https://medicinainterna.org.mx/category/popups/dorixina-flam-siegfried-rhein/", "https://medicinainterna.org.mx/category/editorial/", "https://medicinainterna.org.mx/category/popups/evocs-respitratorias-liomont/", "https://medicinainterna.org.mx/category/popups/expomed/", "https://medicinainterna.org.mx/category/popups/gantena-1-3-kastandi-senosiain/", "https://medicinainterna.org.mx/category/popups/garbican-liomont-sin-ipp/", "https://medicinainterna.org.mx/category/in-memoriam/", "https://medicinainterna.org.mx/category/popups/italdermol-italmex-con-ipp/", "https://medicinainterna.org.mx/category/popups/jarsix-y-nexus-h-cintillos-senosiain/", "https://medicinainterna.org.mx/category/popups/kirruz-italmex-ipp/", "https://medicinainterna.org.mx/category/popups/lactipan-italmex-separador/", "https://medicinainterna.org.mx/category/popups/legalon-meda/", "https://medicinainterna.org.mx/category/popups/lunarium-italmex-con-ipp/", "https://medicinainterna.org.mx/category/popups/lurvimi-ciproflox-dm-cintillos-senosiain/", "https://medicinainterna.org.mx/category/popups/neuroflax-sanfer-con-ipp/", "https://medicinainterna.org.mx/category/popups/nexus-h-cintillo-arfla-senosiain/", "https://medicinainterna.org.mx/category/popups/oksen-tercio-arfla/", "https://medicinainterna.org.mx/category/popups/quadriloid-liomont/", "https://medicinainterna.org.mx/category/popups/quimara-liomont-popups/", "https://medicinainterna.org.mx/category/revision-narrativa/", "https://medicinainterna.org.mx/category/revision-sistematica/", "https://medicinainterna.org.mx/category/rincon-del-internista/", "https://medicinainterna.org.mx/category/popups/rovartal-siegfried-sin-ipp/", "https://medicinainterna.org.mx/category/popups/seltaferon-liomont-sin-ipp/", "https://medicinainterna.org.mx/category/popups/senosiain-biomics-1-3-lurvimi/", "https://medicinainterna.org.mx/category/popups/stadium-sanfer-con-ipp/", "https://medicinainterna.org.mx/category/suplemento/", "https://medicinainterna.org.mx/category/popups/supradol-liomont/", "https://medicinainterna.org.mx/category/popups/thioctacid-meda/", "https://medicinainterna.org.mx/category/popups/ulsicral/", "https://medicinainterna.org.mx/category/popups/viravir-gantena-tercio-senosiain/", "https://medicinainterna.org.mx/category/popups/zinolox-liomont-sin-ipp/", "https://medicinainterna.org.mx/2019/03/", "https://medicinainterna.org.mx/", "https://medicinainterna.org.mx/", "https://medicinainterna.org.mx/nosotros/", "https://medicinainterna.org.mx/nosotros/", "https://medicinainterna.org.mx/aviso-de-privacidad/", "http://#", "https://medicinainterna.org.mx/category/editorial/", "https://medicinainterna.org.mx/category/articulos-originales/", "https://medicinainterna.org.mx/category/caso-clinico/", "https://medicinainterna.org.mx/category/articulo-de-revision/", "https://medicinainterna.org.mx/category/rincon-del-internista/", "https://medicinainterna.org.mx/category/articulo-de-opinion/", "https://medicinainterna.org.mx/category/carta-al-editor/", "https://medicinainterna.org.mx/historico/", "#", "https://medicinainterna.org.mx/autores/", "https://medicinainterna.org.mx/wp-content/uploads/2020/05/Carta-cesion-Med-Int.pdf", "https://medicinainterna.org.mx/ayuda/", "#", "https://medicinainterna.org.mx/", "https://medicinainterna.org.mx/nosotros/", "https://medicinainterna.org.mx/nosotros/", "https://medicinainterna.org.mx/aviso-de-privacidad/", "http://#", "https://medicinainterna.org.mx/category/editorial/", "https://medicinainterna.org.mx/category/articulos-originales/", "https://medicinainterna.org.mx/category/caso-clinico/", "https://medicinainterna.org.mx/category/articulo-de-revision/", "https://medicinainterna.org.mx/category/rincon-del-internista/", "https://medicinainterna.org.mx/category/articulo-de-opinion/", "https://medicinainterna.org.mx/category/carta-al-editor/", "https://medicinainterna.org.mx/historico/", "#", "https://medicinainterna.org.mx/autores/", "https://medicinainterna.org.mx/wp-content/uploads/2020/05/Carta-cesion-Med-Int.pdf", "https://medicinainterna.org.mx/ayuda/", "https://medicinainterna.org.mx/article/inhibicion-de-pcsk9-una-nueva-alternativa-para-reducir-el-colesterol-y-prevenir-la-enfermedad-cardiovascular-aterosclerosa/#respond", "https://medicinainterna.org.mx/category/articulo-de-revision/", "https://medicinainterna.org.mx/descarga/1272/?tmstv=1678281245", "mailto:ahumadam1@hotmail.com", "https://medicinainterna.org.mx/tag/alirocumab/", "https://medicinainterna.org.mx/tag/anticuerpos-monoclonales/", "https://medicinainterna.org.mx/tag/c-ldl/", "https://medicinainterna.org.mx/tag/colesterol/", "https://medicinainterna.org.mx/tag/estatinas/", "https://medicinainterna.org.mx/tag/evolocumab/", "https://medicinainterna.org.mx/tag/inclisiran/", "https://medicinainterna.org.mx/tag/pcsk9/", "https://medicinainterna.org.mx/tag/riesgo-cardiovascular/", "https://www.facebook.com/sharer/sharer.php?u=https://medicinainterna.org.mx/article/inhibicion-de-pcsk9-una-nueva-alternativa-para-reducir-el-colesterol-y-prevenir-la-enfermedad-cardiovascular-aterosclerosa/", "http://twitter.com/share?url=https://medicinainterna.org.mx/article/inhibicion-de-pcsk9-una-nueva-alternativa-para-reducir-el-colesterol-y-prevenir-la-enfermedad-cardiovascular-aterosclerosa/&text=Inhibici%C3%B3n+de+PCSK9%3A+una+nueva+alternativa+para+reducir+el+colesterol+y+prevenir+la+enfermedad+cardiovascular+aterosclerosa", "https://pinterest.com/pin/create/button/?url=https://medicinainterna.org.mx/article/inhibicion-de-pcsk9-una-nueva-alternativa-para-reducir-el-colesterol-y-prevenir-la-enfermedad-cardiovascular-aterosclerosa/&media=https://medicinainterna.org.mx/wp-includes/images/media/default.png&description=Inhibici%C3%B3n+de+PCSK9%3A+una+nueva+alternativa+para+reducir+el+colesterol+y+prevenir+la+enfermedad+cardiovascular+aterosclerosa", "https://plus.google.com/share?url=https://medicinainterna.org.mx/article/inhibicion-de-pcsk9-una-nueva-alternativa-para-reducir-el-colesterol-y-prevenir-la-enfermedad-cardiovascular-aterosclerosa/", "https://medicinainterna.org.mx/author/administrador/", "/article/inhibicion-de-pcsk9-una-nueva-alternativa-para-reducir-el-colesterol-y-prevenir-la-enfermedad-cardiovascular-aterosclerosa/#respond", null, "https://medicinainterna.org.mx/profile/edit/?a=pwdreset", "https://medicinainterna.org.mx/profile/register/", "https://medicinainterna.org.mx/profile/register/?swcfpc=1", "http://dgb.unam.mx/periodica/html", "http://www.latindex.org", "mailto:articulos@nietoeditores.com.mx", "#", "https://medicinainterna.org.mx/?blackhole=33c1784def"]}